A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
Mar 1, 2022
0
39
(HealthDay)—Gender differences extend to cancer treatments, with women having a higher risk of severe side effects from certain treatments than men, a new study finds.
Feb 15, 2022
0
11
A study by researchers at Mayo Clinic Cancer Center in Florida is validating the use of genomic sequencing to predict the likelihood that patients with gastric cancer will derive benefit from chemotherapy or from immunotherapy. ...
Feb 14, 2022
0
38
An immunotherapy drug called pembrolizumab has been shown to significantly reduce disease recurrence in patients with the most aggressive type of breast cancer, according to results from a phase III clinical trial led by ...
Feb 10, 2022
0
13
An experimental form of immunotherapy that uses an individual's own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial ...
Feb 1, 2022
0
95
Immunotherapy given before surgery caused liver cancer tumors to die off in one-third of the patients enrolled in a first-of-its-kind clinical trial, Mount Sinai researchers reported in The Lancet Gastroenterology & Hepatology ...
Jan 20, 2022
0
33
Using data from over 300 patient tumors, UCSF researchers have described 12 classes of "immune archetypes" to classify cancer tumors. Their findings, published this week in Cell, reveal that cancers from different parts of ...
Jan 6, 2022
0
132
Adding messenger RNA, or mRNA therapy improves the response to cancer immunotherapy in patients who weren't responding to the treatment, Mayo Clinic research shows. Immunotherapy uses the body's immune system to prevent, ...
Dec 15, 2021
0
15
In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach. It is based on using humanized antibodies called immune checkpoint inhibitors (ICIs) to block the cellular pathways ...
Dec 7, 2021
0
56
EPFL scientists have found that stiffening the membranes of cancer cells can lead to improved immunotherapy outcomes. Preclinical tests show that it can increase long-term survival rates to nearly 50%.
Dec 7, 2021
0
83
